Ionis Partner Biogen Report Results of Tofersen in P-III (VALOR) study and OLE to Treat SOD1-ALS
Shots:
- The P-III (VALOR) study evaluates tofersen (100 mg) in 108 adults with ALS associated with a SOD1 mutation. Additionally, 95 patients were enrolled in the ongoing OLE
- The 12mos. data showed that earlier initiation of tofersen slowed decline across measures of clinical, respiratory function, strength & QoL, robust & sustained reductions in neurofilament, and early survival data showed a lower risk of death or PV
- 33% & 21% reduction in SOD1 protein, 51% & 41% reduction in plasma neurofilament, serious AEs were reported in 36.5% of patients who received tofersen in (VALOR) or OLE, 17.3% discontinued treatment due to an AE. Tofersen is also being studied in the P-III (ATLAS) study for the same indication
Ref: PRNewswire| Image: Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
